{"id":"W3094745505","doi":"10.1158/1078-0432.ccr-20-1830","title":"OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Ottawa Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Combination therapy; Internal medicine; Rash; Adverse effect; Pharmacodynamics; Oncology; Clinical endpoint; Pharmacology; Cancer; Pharmacokinetics; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004658077,0.000438046,0.0008397956,0.0001724462,0.0001395316,0.0003111849,0.0002179578,0.0002674997,0.001413197],"category_scores_gemma":[0.0002252713,0.0001460028,0.0003942987,0.0001687541,0.0002274652,0.0002415525,0.0001210127,0.0007558175,0.0004589875],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002783829,"about_ca_system_score_gemma":0.0005105545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002837126,"about_ca_topic_score_gemma":0.0008996024,"domain_scores_codex":[0.9998536,0.00005475568,0.00001403772,0.00002288112,0.00002671278,0.00002794317],"domain_scores_gemma":[0.9998653,0.00002103328,0.00004150905,0.000007357066,0.00001120834,0.00005365266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2748382,0.03118596,0.04148456,0.002025275,0.001616186,0.0005482903,0.0002772658,0.003509411,0.2040119,0.0002846083,0.00363486,0.4365834],"study_design_scores_gemma":[0.168721,0.6960191,0.08238096,0.0001353162,0.001343921,0.001711808,0.0001220734,0.002839852,0.03240105,0.0002163017,0.01406564,0.00004297911],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964858,0.002267995,0.00009398113,0.00007835974,0.00002940343,0.0001515284,0.00008563022,0.00001886439,0.0007884628],"genre_scores_gemma":[0.9972423,0.001321984,0.0002701963,0.0001466621,0.00006510086,0.0001026154,0.000276449,0.000003825719,0.0005708135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001413197,"threshold_uncertainty_score":0.004727602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1147904643759577,"score_gpt":0.4554999773211006,"score_spread":0.3407095129451428,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}